 Delcath Systems, Inc. OTCQB:DCTH NASDAQ:DCTH, an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a 22 million underwritten public offering of 2.2 million shares of common stock or common stock equivalents and Series F warrants to purchase up to 2.2 million shares of common stock. Each share of common stock or common stock equivalent is being sold with one Series F warrant to purchase one share of common stock at a combined public offering price of 10.00 per share and related Series F warrant. The offering is expected to close on May 5, 2020, subject to the satisfaction of customary closing conditions. 